Developer of a cell-based platform designed to produce high-quality mRNA for the next generation of mRNA therapeutics and vaccines. The company offers cost-efficient and scalable mRNA production through principles of cell engineering, computational biology, and precision fermentation, enabling the pharmaceutical industry to produce high-quality mRNA for the next generation of mRNA therapeutics and vaccines.

Profile

Social Media

Sensible Biotechnologies Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Miroslav Gasparek

Chief Scientific Officer

Marian Kupculak

Browse more venture capital transactions:

Prev: 4/6/2023: Portrait Analytics venture capital transaction
Next: 4/6/2023: Huddle01 venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary